福森藥業(01652.HK)合營公司江西康德獲注資5018萬元
格隆匯12月24日丨福森藥業(01652.HK)宣佈,於2019年12月24日,江西康德及江西康德股東與投資者訂立注資協議,據此,投資者同意向江西康德注資人民幣5018.0415萬元,以認購江西康德29.9%的股權,其中人民幣426.5335萬元將作為江西康德的額外註冊資本注入,餘下人民幣4591.5080萬元將計入江西康德的資本儲備。由於注資,故投資者以及由公司的全資附屬公司衡盛、費久華及於光組成的江西康德股東將分別持有江西康德約29.9%、35.8%、21.0%及13.3%的股權,據此,就上市規則而言,江西康德不再為公司的附屬公司。於注資後,衡盛於江西康德的股權將由51%攤薄至約35.8%,據此,就上市規則而言,江西康德將不再為公司的附屬公司。
然而,鑑於於公告日期,集團於江西康德的股權以權益法於集團的綜合財務報表入賬為合營企業/聯營公司,故根據相關會計準則,儘管注資,江西康德將仍為公司的合營企業/聯營公司。因此,預期集團將不會因注資而錄得任何重大損益。
於2019年7月12日,公司的全資附屬公司衡盛訂立收購協議收購菏澤市牡丹區華瀚網絡信息技術中心的51%股權,以參與制造及銷售名為凱復定的藥品(化學名稱:注射用頭孢他啶),從而擴大集團的醫藥產品業務及多元化其收入來源。
江西康德為於中國註冊成立的有限公司。江西康德主要從事進出口中藥材、中藥飲片、中成藥、化學原料藥、藥用賦形劑、抗生素原料藥物、生化藥物及相關技術。江西康德現時進口並向中國市場出售凱復定。
於公告日期,江西康德由公司的全資附屬公司衡盛、費久華及於光分別擁有51%、30%及19%的股權。於公告日期,江西康德被視為公司的附屬企業,而集團於江西康德的權益乃使用權益法在集團的綜合財務報表中入賬為合營企業/聯營公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.